Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease

2018 ◽  
Vol 13 (1) ◽  
pp. 5-11
Author(s):  
Maciej Kupczyk ◽  
Piotr Kuna
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Combination Therapy ◽  
Pulmonary Disease ◽  
Beclomethasone Dipropionate ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Glycopyrronium Bromide ◽  
Formoterol Fumarate

New triple combination of beclomethasone dipropionate, glycopyrronium bromide and formoterol fumarate in the treatment of chronic obstructive pulmonary disease

2021 ◽  
Vol 31 (3) ◽  
pp. 365-373
Author(s):  
S. N. Avdeev ◽  
N. V. Trushenko
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Beclomethasone Dipropionate ◽  
New Combination ◽  
Chronic Obstructive ◽  
Triple Combination ◽  
Obstructive Pulmonary Disease ◽  
Glycopyrronium Bromide ◽  
Increased Risk ◽  
Formoterol Fumarate

Therapeutical options for the treatment of chronic obstructive pulmonary disease (COPD) have significantly expanded in recent years, primarily due to market entry of new combination drugs. One of the commonly used therapeutic options for patients with frequent exacerbations of COPD is a triple combination, including LABA, LAMA and ICS, however, prescribing such therapy, doctors often face a decrease in treatment adherence, which ultimately leads to lack of effectiveness, as well as with an increased risk of adverse events. This article presents the current information on the clinical efficacy and safety profile of a fixed triple combination of beclomethasone dipropionate, glycopyrronium bromide and formoterol fumarate, available as extrafine aerosol inhaler, allows to optimize inhalation treatment for patients with frequent exacerbations of COPD.

Sign in / Sign up

Export Citation Format

Share Document